Valneva stock among the strongest gainers in the SBF 120: the share climbs 2.5%

A rebound that leaves the share far from its moving averages

The Valneva share gains 2.72% to €2.60 and ranks among the strongest gainers in the SBF 120, which advances by 0.14%. Over seven days, the share has risen 2.81%, but it has fallen 9.9% over one month, so today's rebound merely mitigates this decline. The price remains below its MA20 and MA50, both close to €2.70 (spread of 3.63%), and more markedly below its MA200 at €3.05.

The move follows the revocation of Ixchiq's authorization in the United Kingdom, unveiled on October 7, following an assessment of the benefit-risk ratio for travelers by the Commission on Human Medicines. The share had then lost 4.5% on October 8, before recovering on Friday. At €2.60, it is trading between its support level of €2.49 and its resistance level of €2.99.

A H1 2026 that confirmed the outlook despite a degraded travel context

When publishing first-half 2026 results on August 13, the group had confirmed its outlook for the fiscal year, despite the persistent impact of the geopolitical context on travel. Among the risks cited were the dependence on IXIARO deliveries to the U.S. Department of Defense and the refocusing of IXCHIQ on endemic markets. On the opportunities side, the company mentioned expected regulatory decisions on its vaccine candidate against Lyme disease within twelve months.

The share is listed on two venues: the ordinary share in Paris, eligible for the PEA, and the ADS on Nasdaq, at a rate of two shares for one ADS. Paris accounts for the bulk of volumes. Over three months, the share maintains a gain of 19.41%, but it remains down 42.48% over one year.